USA flag logo/image

An Official Website of the United States Government

Search


Download to spreadsheetPrint
Displaying 1 – 25 of 126 Awards
Company: VIROGENICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: … mouse or human, a therapeutic that induces transient reduction of CD45 function is very likely to have an excellent safety profile, particularly if only CD45 is targeted. One approach to such selective targeting is to utilze CD45-specific genetic sequences. CD45-specific … more
Company: SAVARA INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: … NanoNucleic technology) was developed at the University of Kansas, and licensed exclusively to Savara Inc, a drug development company specializing in the treatment of lung diseases. The NanoNucleic technology comprises a cationic peptide bundled with DNA (or RNA for siRNA… more
Company: PDX PHARMACEUTICALS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: … therapies typically average about one year due to developed resistance. This represents an area of unmet clinical need. HER2 over-expression has been clearly linked to aggressive and abnonnal tumor growth, rapid metastases, and drug resistance in this cancer subtype. siRNA… more
Company: Extend Biosciences Inc. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: …. Currently, siRNAs are injected intravenously (IV) where they undergo rapid clearance from the body if not formulated with potentially toxic and immunogenic lipid-encapsulating vehicles. In this proposal, we apply our novel carrier technology to a new class of siRNA called… more
Company: SYNTHOMICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2013 / 1
Abstract: … dramatic. It is likely that access to this technology will precipitate an expansion of research as many technologies that are limited by the cost of oligonucleotides will now be possible. Regarding cancer research, the use of synthetic RNA and DNA oligonculeotides in siRNA,… more
Company: RXI PHARMACEUTICALS CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: …, and other CNS malignancies.Moreover, transient MYC down-regulation appears to be well tolerated at the organismal level, while dramatically suppressing tumorigenesis. However, MYCN proteins are considered to be 'undruggable' at the present time. siRNA-based drugs… more
Company: AM BIOTECHNOLOGIES, LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … siRNAs targeting 2-secretase. In Phase II, AM will (a) scale reagent production up to commercial quantities and purity; (b) optimize a robust protocol for synthesis of PS2-2'-F-RNA; (c) evaluate the effects of PS2-2'-F modifications on aptamers and siRNA activity in… more
Company: DORMATARG, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: …f two lead compounds in order to link them to magnetic beads or perform photoaffinity labeling without destroying the activity of the molecule. The second aim is to extract the target protein for identification by mass spectrometry and validate its identity by siRNA knockdown of… more
Company: OPTIMUM THERAPEUTICS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: …at a new approach is needed for the remaining patients who are not adequately managed by intravesical MMC therapy. Survivin is a marker/predictor of bladder cancer aggressiveness and recurrence. We have developed a pegylated cationic lipid carrier (PCat) for survivin siRNA that… more
Company: SIRNAOMICS, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … such as transforming growth factor-ss1 (TGF-ss1), and COX-2 are upregulated in adult tissue and show reduced expression in fetal skin. Using RNA interference (RNAi) to down regulate a target gene expression, we have previously demonstrated that a multi-targeted siRNA… more
Company: TISSUETECH, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … of the corneoscleral rim normally discarded after conventional corneal transplantation. Thus, in this Phase I application, we would like to prove the concept that the size of HCEC monolayers can further be enlarged by optimizing the regimen of p120- catenin siRNA knockdown… more
Company: ADVANCED RNA TECHNOLOGIES, LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … new RNAi platform that enables gene studies in a biologically relevant context with a long term goal of building a functional map of human genome. Introduction of small interfering RNAs (siRNAs) into cells with transfection reagents results in efficient gene silencing. … more
Company: ENGINEERING ARTS, LLC Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: DESCRIPTION (provided by applicant): Every gene has its own set of small RNA molecules, known as small interfering RNA (siRNA), that inhibit expression of the gene's proteins. The siRNA molecules are part of an ancient natural mechanism of gene… more
Company: INFINITESIMAL LLC Agency/Program/Year/Phase: HHS / STTR / 2012 / 1
Abstract: … tip that creates a small rupture in the cell membrane while the outer shell guides biomolecules to the point of injection. Picoliter control in fluid injection Large scale genomic and proteomic studies require delivery of drugs, conjugated nanoparticles, DNA, siRNA, and… more
Company: INFINITESIMAL LLC Agency/Program/Year/Phase: NSF / SBIR / 2012 / 1
Abstract: …, and the ability to control injection volumes at the picoliter level. Injection of large number of cells is necessary for drug discovery and associated large scale genomic and proteomic studies. Such studies require delivery of drugs, conjugated nanoparticles, DNA, siRNA,… more
Company: ENSYSCE BIOSCIENCES, INC. Agency/Program/Year/Phase: HHS / SBIR / 2012 / 1
Abstract: … as other critical carbon nanotube patents, have been in-licensed or applied for by Ensysce and the company has initiated a number of research programs to utilize carbon nanotubesto treat cancer including that described herein to deliver short interfering RNAs (siRNA).… more
Company: RXI PHARMACEUTICALS CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: DESCRIPTION (provided by applicant): Introduction of small interfering RNAs (siRNAs) into cells with transfection reagents results in potent and specific gene silencing by RNA interference (RNAi). Unfortunately, while siRNA-based drugs represent a potentially significant… more
Company: RXI PHARMACEUTICALS CORPORATION Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: … is caused by dominantly transmitted mutations in the gene encoding cytosolic superoxide dismutase (SOD1). Transgenic expression of mutant SOD1 causes ALS in mice. In thesemice, suppression of expression of the transgene using either antisense oligonucleotides or siRNA slows… more
Company: AuraSense, LLC Agency/Program/Year/Phase: DOD / SBIR / 2011 / 1
Abstract: … in the control of gene and protein expression. Objective 1 experiments will be designed to demonstrate and optimize: 1) Ability to deliver conjugate nanostructures into both prokaryotic and eukaryotic cells, 2) Ability to deliver oligonucleotides including siRNA, DNA… more
Company: AM BIOTECHNOLOGIES, LLC Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: … of siRNAs targeting 2-secretase. In Phase II, AM will (a) scale reagent production up to commercial quantities and purity; (b) optimize a robust protocol for synthesis of PS2-2'OMe-RNA; (c) evaluate the effects ofPS2-2'-OMe modifications on aptamers and siRNA… more
Company: BOSTON BIOMEDICAL, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: … RNAi to specifically down-regulate the expression of any gene has had a profound impact on the study of gene function, and holds great promise for in vivo functional genomics. The current paradigm for inducing RNAi in mammalian cells relies on the use of a 21-bp siRNA… more
Company: Innovative Surface Technologies, Inc. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 1
Abstract: … acid carrier under development at Innovative Surface Technologies, Inc. (ISurTec) for universal transfection of neurons in vitro and in vivo. This technology is platform-based and consists of a polymeric nanoparticle for high-efficiency non-viralgene and siRNA… more
Company: LNKCHEMSOLUTIONS Agency/Program/Year/Phase: HHS / SBIR / 2011 / 2
Abstract: … imaged-guided treatment of brain tumors. Throughout the study period, NPs will be manufactured at LNK and subsequently tested at UCH. In Aim 1, we will use both in vitro and animal models to critically examine NPs for targeting and delivery of chemotherapy and siRNA. After… more
Company: TRANSDERM, INC. Agency/Program/Year/Phase: HHS / SBIR / 2011 / 2
Abstract: …, in the genes encoding keratins 6, 16, and 17. The major complaint of PC patients is the debilitating painful callusing and blistering which occurs on or near the pressure points of the feet. These defined regions on the soles of the feet were targeted for local siRNA… more
Company: Molecular Templates Agency/Program/Year/Phase: NSF / SBIR / 2011 / 1
Abstract: This Small Business Innovation Research (SBIR) Phase I project will demonstrate targeted delivery of small interfering RNA (siRNA) to HER2 overexpressing tumor cells using a unique Shiga-like toxin 1A (SLT1A) scaffold. Molecular Templates has developed a SLT1A library of… more
Displaying 1 – 25 of 126 Awards
Narrow Your Search
By Agency
By Year
By Phase
By Program
By State
By Company Ownership
By Company
HELP FOR NARROW YOUR SEARCH

Search Options

There are several categories such as “By Agency”, “By Year”, “By State” etc. Select a checkbox within a category to refine your search results.

Each of your selections is listed in the “Narrow Search Filters” bar. You can uncheck these selections to remove them.


Search for Either Criteria

When you select multiple values within a category, the results will include values that match either of the selections. For example, selecting “2005” and “2007” in the “By Year” category will display results that include either 2005 OR 2007 in the results.


Narrowing the Search Results

You can refine your search results across categories. To narrow down your results, select multiple values across different categories. The results will only include values that match the selections across the categories. For example, selecting “2005” in the “By Year” category and “NASA” in the “By Agency” category will only display the results that contain both “2005” AND “NASA” in the results.